Anrotinib in Combination With Capecitabine in Advanced Triple Negative Breast Cancer
Status:
Recruiting
Trial end date:
2022-12-31
Target enrollment:
Participant gender:
Summary
The hypothesis of this study is to discover if the capecitabine plus Anlotinib can shrink or
slow the growth of pretreated advanced TNBC.
It is a single-arm phase II clinical study of capecitabine combined with antinib in the
treatment of recurrent or metastatic triple-negative breast cancer